Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ET-STEM in Frontotemporal Dementia
NCT05315661Phase 1Active, not recruiting
- Sponsor
- Samsung Medical Center
- Start
- Jul 2022
- Primary completion
- Dec 2026
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ET-STEM in frontotemporal dementia (FTD), sponsored by Samsung Medical Center. Primary endpoints: Dose Limiting Toxicity at 3 weeks and Adverse Events at 5 years. Started Jul 2022; status: active, not recruiting.
02
Drugs
ET-STEM
03
Conditions
frontotemporal dementia (FTD)
Beyond the preview
Go deeper on NCT05315661.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05315661.